Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.
Grant A. McArthur
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Millennium; Novartis; Roche/Genentech
Research Funding - Millennium; Novartis; Pfizer
Jason Callahan
No relevant relationships to disclose
Antoni Ribas
Consultant or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Merck
Stock Ownership - Kite Pharma
Rene Gonzalez
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Anna C. Pavlick
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Bristol-Myers Squibb; Genentech
Omid Hamid
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Thomas Gajewski
Consultant or Advisory Role - AbbVie; Amgen; Bayer; Boehringer Ingelheim; Dendreon; Jounce Therapeutics; Roche/Genentech
Research Funding - Bristol-Myers Squibb; Incyte; Merck; Ono Pharmaceutical ; Roche/Genentech
Igor Puzanov
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Adil Daud
Research Funding - Bristol-Myers Squibb; Genentech; Merck; Pfizer
Ming Yin
Employment or Leadership Position - Roche/Genentech
Nicholas Choong
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Jinay K Shah
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Jill Fredrickson
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Rodney J Hicks
Research Funding - Roche/Genentech